Tom Doan

Mr. Doan joined Vera from Gilead Sciences, Inc., where he most recently served as Executive Director, Clinical Operations Head of the Inflammation/Respiratory Therapeutic Area providing oversight to a pipeline of eight molecules in development from proof-of-concept to pivotal trial programs.

During his 13-year tenure at Gilead, Doan worked across three therapeutic areas, assuming lead roles in clinical development programs including several that led to successful global market filings for Stribild, Complera, Sovaldi, Epclusa and filgotinib.

Before Gilead, Doan led development and post-marketing solid tumor clinical studies at Genentech for Avastin.

Early in his career, he worked at CROs where he developed a strong knowledge of the clinical trial services industry.